Cargando…

Multiple-dose up-titration study to evaluate the pharmacokinetics, safety and antitumor activity of apatinib in advanced gastric adenocarcinoma

BACKGROUND AND PURPOSE: The objective of this study was to investigate the pharmacokinetics, safety, and antitumor activity of apatinib, a vascular endothelial growth factor receptor 2 inhibitor, in advanced gastric adenocarcinoma or gastroesophageal junction adenocarcinoma and evaluate the effect o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Yonggang, Wang, Chang, Zhang, Yanqiao, Hao, Jiqing, Yang, Nong, Wang, Jvfeng, Peng, Min, Liu, Tianshu, Zhang, Guifang, Zhan, Xianbao, Zeng, Shan, Zhang, Yifan, Gao, Yong, Yao, Yang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9623328/ https://www.ncbi.nlm.nih.gov/pubmed/36330490 http://dx.doi.org/10.3389/fonc.2022.876899

Ejemplares similares

Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
por: Liu, Xinyang, et al.
Publicado: (2017)

Correction to: Early presence of anti-angiogenesis-related adverse events as a potential biomarker of antitumor efficacy in metastatic gastric cancer patients treated with apatinib: a cohort study
por: Liu, Xinyang, et al.
Publicado: (2018)

Effect of X-ray radiation on the pharmacokinetics of apatinib in vivo in rats
por: Dong, Shi-Qi, et al.
Publicado: (2022)

Concurrent apatinib and docetaxel vs apatinib monotherapy as third- or subsequent-line therapy for advanced gastric adenocarcinoma: a retrospective study
por: Lin, Haimin, et al.
Publicado: (2019)

Apatinib suppresses cell growth and metastasis and promotes antitumor activity of temozolomide in glioma
por: Wang, Chao, et al.
Publicado: (2018)

Efficacy of Drug-Eluting Beads Transarterial Chemoembolization Plus Apatinib Compared with Conventional Transarterial Chemoembolization Plus Apatinib in the Treatment of Unresectable Hepatocellular Carcinoma
por: Zhang, Weihua, et al.
Publicado: (2021)

Apatinib enhances the antitumor effects of radiation in HeLa cell line mouse model of invasive cervical cancer
por: Wang, Yun, et al.
Publicado: (2022)

Apatinib Combined With Radiotherapy Enhances Antitumor Effects in an In Vivo Nasopharyngeal Carcinoma Model
por: Liu, Shanshan, et al.
Publicado: (2020)

Advanced Hepatocellular Carcinoma With Hepatic Arterioportal Shunts: Combination Treatment of Transarterial Chemoembolization With Apatinib
por: Sun, Tao, et al.
Publicado: (2020)

The apatinib and pemetrexed combination has antitumor and antiangiogenic effects against NSCLC
por: Zhou, Ling, et al.
Publicado: (2023)

Effects of Apatinib on the Pharmacokinetics of Nifedipine and Warfarin in Patients with Advanced Solid Tumors
por: Zhu, Yun-Ting, et al.
Publicado: (2020)

Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma: A case report and review of the literature
por: Zhang, Chu, et al.
Publicado: (2020)

Apatinib in the treatment of advanced lung adenocarcinoma with KRAS mutation
por: Zeng, Da-xiong, et al.
Publicado: (2017)

Apatinib enhances chemosensitivity of gastric cancer to paclitaxel and 5-fluorouracil
por: Xu, Zhiyuan, et al.
Publicado: (2019)

Effect of apatinib on the pharmacokinetics of tramadol and O-desmethyltramadol in rats
por: Bao, Su-su, et al.
Publicado: (2023)

Sintilimab Plus Apatinib and Chemotherapy as Second‑/Third-Line treatment for Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: a prospective, Single-Arm, phase II trial
por: Zhang, Le, et al.
Publicado: (2023)

Camrelizumab combined with apatinib and S-1 as second-line treatment for patients with advanced gastric or gastroesophageal junction adenocarcinoma: a phase 2, single-arm, prospective study
por: Jing, Chao, et al.
Publicado: (2022)

The Efficacy of Transarterial Chemoembolization plus Apatinib or Sorafenib in the Treatment of Advanced Hepatocellular Carcinoma
por: Chen, Lei, et al.
Publicado: (2021)

Apatinib combined with S-1 as second-line therapy in advanced gastric cancer
por: Qiu, Zhi-Yuan, et al.
Publicado: (2021)

Efficacy and safety of apatinib for the treatment of AFP-producing gastric cancer
por: Li, Ningning, et al.
Publicado: (2020)

Impact of apatinib in combination with osimertinib on EGFR T790M-positive lung adenocarcinoma
por: Liu, Yang, et al.
Publicado: (2019)

Raltitrexed Enhances the Antitumor Effect of Apatinib in Human Esophageal Squamous Carcinoma Cells via Akt and Erk Pathways
por: Zhen, Hongchao, et al.
Publicado: (2020)

Expression of p53 as a biomarker in determining response to apatinib for advanced gastric cancer
por: Qiu, Zhiyuan, et al.
Publicado: (2023)

Transarterial Chemoembolization Combined With Apatinib for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis
por: Kan, Xuefeng, et al.
Publicado: (2020)

Apatinib as targeted therapy for sarcoma
por: Li, Feng, et al.
Publicado: (2018)

Efficacy and safety for Apatinib treatment in advanced gastric cancer: a real world study
por: Zhang, Yong, et al.
Publicado: (2017)

Application of physiologically-based pharmacokinetic/pharmacodynamic models to evaluate the interaction between nifedipine and apatinib
por: Liu, Hongrui, et al.
Publicado: (2022)

Combined aspirin and apatinib treatment suppresses gastric cancer cell proliferation
por: Zhang, Wei, et al.
Publicado: (2017)

Evaluation of second-line apatinib plus irinotecan as a treatment for advanced gastric adenocarcinoma or gastroesophageal conjunction adenocarcinoma: a prospective, multicenter phase II trial
por: Qu, Jinglei, et al.
Publicado: (2023)

Improved Antitumor Efficacy and Pharmacokinetics of Bufalin via PEGylated Liposomes
por: Yuan, Jiani, et al.
Publicado: (2017)

Safety and efficacy of apatinib in patients with advanced gastric or gastroesophageal junction adenocarcinoma after the failure of two or more lines of chemotherapy (AHEAD): a prospective, single-arm, multicenter, phase IV study
por: Li, Jin, et al.
Publicado: (2023)

Combination of apatinib mesylate and second-line chemotherapy for treating gastroesophageal junction adenocarcinoma
por: Lu, Bin, et al.
Publicado: (2019)

Safety and effectiveness of apatinib in elderly patients with metastatic gastric cancer: a sub-analysis from the large-scale, prospective observational study of apatinib for gastric cancer treatment in a real-world clinical setting (AHEAD-G202)
por: Wang, Xiang, et al.
Publicado: (2022)

The prognostic value of baseline hematological parameters of peripheral blood in metastatic gastric cancer treated with apatinib
por: Yang, Jin-Ru, et al.
Publicado: (2022)

An open label, multicenter, noninterventional study of apatinib in advanced gastric cancer patients (AHEAD-G202)
por: Wang, Xiang, et al.
Publicado: (2020)

Apatinib in the treatment of gastric cancer in Henan Province: a multicenter prospective real-world observational study (Ahead-HAP01)
por: Ma, Yijie, et al.
Publicado: (2022)

Neoadjuvant apatinib combined with oxaliplatin and capecitabine in patients with locally advanced adenocarcinoma of stomach or gastroesophageal junction: a single-arm, open-label, phase 2 trial
por: Tang, Zhaoqing, et al.
Publicado: (2022)

Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug–Drug and Drug–Disease Interactions of Apatinib
por: Liu, Hongrui, et al.
Publicado: (2021)

Effectiveness and safety of low‐dose apatinib in advanced gastric cancer: A real‐world study
por: Du, Yingying, et al.
Publicado: (2020)

DUSP1 induces apatinib resistance by activating the MAPK pathway in gastric cancer
por: Teng, Fei, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_25gfj95i4ega67lqs3g3dc88gu